Clinical Trial Update: A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS) [Phase 1]

View source ↗

Summary

Phase 1 PET study assessing TAK-041’s effect on amphetamine-induced dopamine release in healthy volunteers; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers

Drugs mentioned

• TAK-041 (TAK-041)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Healthy Volunteers | Phase 1 | Status: COMPLETED | Results posted: 2019-12-23